Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study - 10/03/21
, Lene Dreyer, MD, PhD b, Mathias Bo Ottosen, MSC a, Gunnar Gislason, MD, PhD c, Kristian Kofoed, MD, PhD a, Alexander Egeberg, MD, PhD a
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
Limited data suggest that hydroxychloroquine may affect risk of cardiovascular disease in patients with lupus erythematosus (LE).
Objective |
To investigate whether hydroxychloroquine treatment is associated with major adverse cardiovascular events (MACE) (myocardial infarction, ischemic stroke, or cardiovascular-associated death) in patients with cutaneous LE (CLE) or systemic LE (SLE).
Methods |
Based on the Danish nationwide registers, an observational cohort study was conducted including patients with first-time diagnosis of CLE or SLE (between 1997 and 2017). Cox regression models calculating the hazard ratio (HR) analyzing the risk of MACE were performed comparing time on and off hydroxychloroquine (including never users). The models were adjusted for age, sex, socioeconomic status, concomitant treatment, and cardiovascular risk factors.
Results |
Among 4587 patients with LE, 51% (n = 2343) were treated with hydroxychloroquine during the study period. An inverse association between use of hydroxychloroquine and MACE risk was observed among patients with SLE (adjusted HR, 0.65; 95% confidence interval, 0.46-0.90) and patients with CLE (adjusted HR, 0.71; 95% confidence interval, 0.42-1.19). Consistent results were found in sensitivity analyses including a case-time control design.
Limitations |
No information on disease activity/severity was available.
Conclusion |
Our findings indicate an opportunity to reduce the risk of cardiovascular events in patients with LE through use of hydroxychloroquine.
Le texte complet de cet article est disponible en PDF.Key words : cardiovascular disease, cutaneous lupus erythematosus, hydroxychloroquine, major adverse cardiovascular event, systemic lupus erythematosus
Abbreviations used : CI, CLE, CVD, HR, IL, IR, HCQ, LE, MACE, MI, OR, PPV, SLE
Plan
| Funding sources: None. |
|
| IRB approval status: None. |
Vol 84 - N° 4
P. 930-937 - avril 2021 Retour au numéro
Article précédent
- Narrow resection margins are not associated with mortality or recurrence in patients with Merkel cell carcinoma: A retrospective study
- Frédéric Jaouen, Thibault Kervarrec, Agnès Caille, Yannick Le Corre, Brigitte Dreno, Eric Esteve, Ewa Wierzbicka-Hainaut, Hervé Maillard, Monica Dinulescu, Astrid Blom, Philippe Saïag, Mahtab Samimi
- Performance of Salamanca refinement of the T3-AJCC8 versus the Brigham and Women's Hospital and Tübingen alternative staging systems for high-risk cutaneous squamous cell carcinoma
- Laura Puebla-Tornero, Luis Antonio Corchete-Sánchez, Alberto Conde-Ferreirós, Natalia García-Sancha, Roberto Corchado-Cobos, Concepción Román-Curto, Javier Cañueto
Bienvenue sur EM-consulte, la référence des professionnels de santé.